International Consultancy in Innovative Manufacturing and Quality/Safety of Blood-Derived Bio Produc, London, United Kingdom
Jerard Seghatchian is an internationally respected authority consulting in the field of apheresis science and transfusion science/medicine. He has particular expertise concerning quality assessment/assurance and DDR strategies of blood components, ensuring the clinical safety/efficacy and overall quality aspects of the blood supply. Currently, he serves as a senior editor of TRASCI with a particular interest in the generation of cellular derived microparticles during storage and their post-transfusion effects.Highlighting a productive scientific career that spans more than four decades, he has published 400+ peer reviewed articles.
Review Article
Passive Immunotherapy Using Approved Vaccines for the Management the Evolving Fast Spreading SARS Cov-2 Variants: A Personal Viewpoint from the UK Perspectives
Author(s): Jerard Seghatchian*
The current use of the IT tools, so called, Artificial Intelligence in the procedural, patterns and large data analyses have proven to be extremely useful in establishing some newer generation of drug therapy. This manuscript aimed to provide an update on the current status of passive immunotherapy, using the two currently approved vaccines that appear to provide a balance amount of CoV-2 neutralizing antibodies, after 3-4 weeks to individuals in need for either preventative or therapeutic intervention... View More»
DOI:
10.35248/igoa.21.6.142